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INTRODUCTION
Light can be used to control where, when and to what extent active species are released from stable, non-biologically active parent molecules. 1 Besides offering a high level of spatiotemporal control, light does not contaminate the living system and its wavelength and intensity can be precisely regulated. 2 A promising approach consists of introducing photocleavable protecting groups (PPGs or caging groups) 1b,3 in key positions of the molecule whose biological activity has to be suppressed temporarily. As a result, the active species from the resulting caged compound will be released only upon light irradiation, leading to the expected biological effect at the desired target site. The approach of using caging groups to regulate the activity of molecules with light has found a widespread application 1-3 both to cage small compounds 4 and larger biomolecules such as peptides and proteins 5 and oligonucleotides. 6 Caged peptides can be prepared by introduction of PPGs at the side chain of trifunctional amino acids by taking advantage of the amino (Lys), carboxylate (Asp and Glu), thiol (Cys) and hydroxyl (Ser, Thr and Tyr, and their phosphorylated derivatives) functions. 7 In addition, caging groups have been introduced at the peptide backbone 8 and, very recently, a bisbipyridyl ruthenium(II) complex has been used to cage histidine residues. 9 However, most reported peptide caging groups based on organic chromophores (e.g. o-nitrobenzyl derivatives or the first-generation of coumarins) require irradiation with shorter wavelengths (UV or blue light)
for uncaging, which compromise in vivo applications due to their poor capacity of penetration into tissues 10 and known photocytotoxicity.
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Among receptors overexpressed on tumour cells, integrins are particularly attractive targets since they have been linked to tumour angiogenesis, which is an essential process for tumour growth and metastasis. 12 Moreover, integrins are frequently overexpressed in tumour endothelial cells as well as on various tumour cells. Owing to the ability of some integrin subtypes (especially α V β 3 ) to selectively recognize the tripeptide motif -Arg-Gly-Asp-, RGD-containing peptides, particularly the conjugable version of Cilengitide, c(RGDfK), have been used for tumour imaging and for targeted drug delivery of cytotoxic compounds, 13 including metal-based anticancer agents. 14 In recent years, only few examples of caged versions of RGD peptides have 4 been described by modifying the Asp residue 7ce with a photolabile protecting group or by incorporating an o-nitrobenzyl group within the backbone skeleton. 8a The fact that such caging groups prevent integrin recognition has been exploited to control integrin-mediated cell adhesion to surfaces by using UV light.
Taking into account the potential of caged peptides in photocontrolled targeted drug delivery therapies and as tools to study of and interfere with complex biological processes, 2 triggering the uncaging process with wavelengths of light compatible with biological entities is highly appealing. Here we report for the first time the solid-phase synthesis of a cyclic RGDcontaining peptide that has been caged at the side chain of the Asp residue with a dicyanocoumarin derivative, which allows photoactivation to be efficiently performed with green light (Figure 1 ). By synthesizing its ruthenocenoyl conjugate, we have also demonstrated that the uncaging process can be triggered in the presence of a metallodrug model cargo, which opens the door to the use of this caged RGD peptide or other dicyanocoumarin-caged peptide sequences in photocontrolled targeted anticancer therapies. 
RESULTS AND DISCUSSION

Synthesis and photochemical properties of coumarin-caged Asp derivatives
Coumarinylmethyl derivatives have been used to cage carboxylic acid functions through esterification, being particularly interesting the high red-shifted absorption of the 7-(N,Ndiethylamino) series. 15 Upon irradiation, a solvent-assisted photoheterolysis produces the free carboxylate from the caged carboxylic acid and a solvent-trapped coumarin as a photo byproduct. 16 Recently, del Campo and collaborators 7e have found that protection of the side chain of Asp during solid-phase peptide synthesis (SPPS) is more convenient with DEACE coumarin
(1) than with the classical DEACM (2) (Scheme 1). 7e The reason relies on the steric hindrance provided by the methyl group incorporated in the coumarin moiety that led to an increase of the stability of the ester bond during the Fmoc-removal basic treatment as compared with the parent DEACM. Based on these precedents, we first focused on modifying the lactone function of the N-(9-fluorenylmethoxycarbonyl) (Fmoc)-protected Asp derivatives 3 and 4 7e (Scheme 1) with the aim of studying: 1) if uncaging could be triggered by green light (> 500 nm), and 2) their compatibility with Fmoc-tBu solid-phase peptide synthesis (SPPS) procedures for synthesizing a caged cyclic RGD peptide. As shown in Scheme 1, four new caged Asp derivatives have been synthesized by replacing the carbonyl group of the coumarinyl moiety by thiocarbonyl (5 and 6) or by dicyanomethylene (7 and 8), since both approaches are known to cause a significant redshift absorption of the coumarin chromophore 15b,17 which has been exploited to uncage model carboxylic acids and amines with blue light.
The synthesis of the new Asp monomers (5-8) was planned from 3 and 4, which were prepared from DEACM and DEACE coumarins following previously reported procedures with minor modifications. The synthesis of the thionated derivatives was carried out by reaction with
Lawesson's reagent in toluene at 70ºC for 12 h. Compounds 5 and 6 were isolated by silica gel column chromatography in good yields (81 and 80%, respectively) and fully characterized by UV-vis, HR-ESI MS and NMR. According to the higher reactivity of the Lawesson's reagent for lactones than for esters, 18 thionation occurred exclusively at the coumarin protecting group (DEACM or DEACE) rather than in the ester or carbamate functions of the amino acid moiety.
Indeed, the chemical shift of the carbonyl group of the lactone in the 13 C NMR spectra of 4 (161.7 ppm) was shifted by ca 36 ppm in 6 (197.0 ppm) due to thionation, and the adjacent proton in 1 H NMR was shifted from 6.1 ppm (4) to 7.0 ppm (6). Similar effects were observed with compound 5. The dicyanomethylenecoumarinyl-Fmoc-protected Asp derivatives were obtained by condensation of the respective thionated precursors with malononitrile in the presence of triethylamine and silver nitrate (Scheme 1) in 81% (7) and 65% (8) yield after silica gel column chromatography and fully characterized by UV-vis, HR ESI MS and NMR. The purity of the amino acid derivatives was also assessed by reversed-phase HPLC ( Figure S1 in the Supporting Information). It is worth noting that amino acid derivatives 5 and 7 were isolated as a mixture of two diastereomers due to the additional stereogenic center created by the incorporation of the methyl group at the coumarin skeleton.
Scheme 1. Synthesis of the coumarin-caged Fmoc-protected Asp derivatives (5-10).
As a next step the compatibility of the four Asp monomers with Fmoc-tBu SPPS was studied Figures S4-S5 ), as well as in cell culture medium (DMEM supplemented with 25% fetal bovine serum) after incubation for 1 h at 37ºC ( Figure S6 ). The latter is a prerequisite for exploring the biological applications of coumarin-caged peptides.
On the basis of the stability studies, we selected dicyanomethylenecoumarin (DEAdcCE and DEAdcCM) as a caging group of Asp and focused on studying the photophysical and photochemical properties of 7 and 8 (see Table 1 and Figures 2 and S7-S10). The UV-vis absorption spectra of both compounds are very similar with an absorbance maximum around 500 nm belonging to * transitions of the coumarin chromophore. As shown in Table 1 ,  max values were slightly red-shifted with respect the corresponding free dicyanocoumarin alcohols (11 and 14; the structures are shown in Scheme 2), which correlates with the tendency previously found in other compounds. 15b Similarly, the fluorescence emission maxima upon excitation at  max was also shifted to longer wavelengths in the caged amino acids. On the basis of the shape of the absorption curve and of the molar extinction coefficients of both DEAdcCM-and DEAdcCE-caged Asp derivatives at their  max and at 505 nm (Table 1) , we decided to evaluate if green light could be used to deprotect them efficiently, because it is less harmful to cells and penetrates deeper in tissues than UV or blue light. 10, 11 Photolysis studies were carried out by using a LED as a light source and the course of the uncaging process was monitored by reversed-phase HPLC-ESI MS. As shown in Scheme 2 and in Figures S11-S12, irradiation at 505 nm induced conversion to the uncaged Fmoc-Asp-OtBu and the corresponding coumarin alcohol derivatives in both cases as the main photolytic by-products (11 from 7 and 14 from 8). The fact that uncaging of 7 was slightly faster compared with that of 8 (2 min vs 5 min, for a complete deprotection) can be attributed to the higher stability of the secondary carbocation intermediate generated during photoheterolysis 16 of the ester bond of 7.
In good agreement with such photolysis studies, the uncaging quantum yield () for 7 was higher than for 8 (Table 1) , resulting in a high product (x), thereby indicating a higher efficiency for the uncaging process.
1b Scheme 2. Photoactivation of dicyanocoumarin-caged Asp monomers.
Synthesis of a dicyanocoumarin-caged cyclic RGD peptide
The next step involved the evaluation of both dicyanomethylenecoumarin derivatives (DEAdcCM and DEAdcCE) as PPGs of the side chain of Asp during the Fmoc-tBu SPPS of a linear pentapeptide containing the RGD sequence (15 and 16, respectively; see Scheme 3). First, compounds 7 and 8 were reacted with HCl in dioxane for 15 h at 50ºC to remove the tert-butyl group, affording the corresponding caged Asp monomers 9 and 10, respectively (Scheme 1) suitable for the assembly of the peptide. As shown in Scheme 3, the assembly of the linear tetrapeptide was carried out on 2-chlorotrityl chloride resin using DIPC and HOAt. After incorporation of both Asp monomers (9 or 10) and Fmoc removal using standard conditions (20% piperidine in DMF), an acidic treatment was carried out to check the quality of the crude peptide. To our surprise, HPLC-ESI MS analysis (Figures S13 and S14 in the Supporting Information) revealed that protection of Asp with both dicyanocoumarin derivatives promotes the formation of an aspartimide side product (17, Scheme 3). In fact, the use of DEAdcCM monomer (10) did not afford the expected peptide (16) after standard piperidine treatment but the corresponding aspartimide derivative as a major product (Table S1 in the Supporting Information). By contrast, this undesired cyclization was substantially reduced with monomer 9, which facilitated peptide 15 to be obtained in a 1:1 ratio with respect 17. Aspartimide formation is well known to occur during the piperidine-catalyzed Fmoc removal of peptides containing Asp and it is very dependent on several factors including the side chain protecting group of this amino acid and its neighboring residue 19 (D-amino acids are known to increase aspartimide formation and in our case D-Phe is adjacent to the dicyanocoumarin-esterified Asp). Since the addition of organic acids to the standard piperidine-based Fmoc deprotection cocktail has been described to reduce the formation of aspartimide side products, we evaluated the use of three additives. 20 As shown in Figures S13 and S14 and in Table S1 , HOBt and Oxyma were very effective in reducing this side reaction, particularly when the sterically-shielded DEAdcCE monomer (9) was used. However, the level of aspartimide was still very high with DEAdcCM monomer (10) under the optimal conditions for 9. The overall results confirm that the steric hindrance provided by the methyl group of DEAdcCE around the -carboxyl ester in combination with HOBt or Oxyma additives during Fmoc-removal represents the best choice to minimize the nucleophilic attack of the amidate anion at the carbonyl group and for instance to reduce aspartimide formation. Taking into account the synthetic problems encountered with DEAdcCM monomer (10) together with its slow photodeprotection rate with green light, we selected DEAdcCE monomer (9) to synthesize the target caged cyclic RGD peptide, c(RGD(DEAdcCE)fK) (18) 
Synthesis and photochemical properties of a conjugate between ruthenocene and the dicyanocoumarin-caged cyclic RGD peptide
Having at hand peptide 18, we conjugated ruthenocene 21 as a metallodrug model cargo to evaluate the compatibility of a metal complex with uncaging conditions. As shown in Scheme 4, ruthenocene carboxylic acid was attached to 18 by using HATU and DIPEA. Analysis by HPLC-ESI MS showed a main peak ( Figure S17 ), which was isolated and characterized as the expected ruthenocene conjugate (20) . Similarly, the control ruthenocene-RGD conjugate (21) was obtained by using peptide 19 ( Figure S19 Finally, the photoactivation of the coumarin-caged peptide (18) and its ruthenocene conjugate (20) was studied. As shown in Figure 3 , both compounds strongly absorb in the visible region showing a maximum of absorption at  max = 496 nm, which was slightly red-shifted with respect monomer 7 (492 nm). Irradiation of 18 at 505 nm caused a fast release of the free peptide 19 (90% after 10 min irradiation at 37 o C in PBS buffer) and the corresponding coumarin alcohol 11 ( Figure S21 ). By contrast, uncaging of conjugate 20 was slightly slower and required 30 min to achieve a similar percentage of deprotection (Figures 3 and S22 ), which could be attributed both to the different medium employed in the experiments and to the presence of the metal complex.
A similar tendency was found when comparing the uncaging quantum yields of the caged peptide (10 2 0.85) and of the conjugate (10 2 0.72). Importantly, only ruthenocenec(RGDfK) conjugate 21 was photoreleased from 20 upon green light irradiation, which indicates that uncaging conditions are completely compatible with the integrity of the bioconjugate. In addition, the stability of the ruthenocenoyl conjugate in cell culture medium (DMEM-25% FBS, 1 h 37ºC; Figure S23 ) opens the door to using dicyanocoumarin-caged RGD peptides as drug carriers in cells overexpressing α V β 3 integrins. 
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CONCLUSIONS
In summary, we have described for the first time the synthesis and photochemical characterization of a caged cyclic RGD peptide that can be efficiently photoactivated with biologically-compatible green light. This was accomplished by using a new dicyanocoumarin derivative (DEAdcCE) for the protection of the carboxyl group at the side chain of the aspartic acid residue, which was selected on the basis of Fmoc-tBu SPPS compatibility and photolysis efficiency. Indeed, the acid and basic stability of dicyanocoumarin-caged Asp monomers (7 and 8) was found to be substantially higher than that of the thiocoumarin precursors (5 and 6) and, among them, the DEAdcCE moiety was preferred over DEAdcCM due to higher uncaging efficiency and reduced aspartimide formation. Minimization of aspartimide side-reaction was accomplished by using acidic additives such as HOBt or Oxyma during the basic Fmoc-removal treatment in combination with the Fmoc-Asp(DEAdcCE)-OH monomer (9) in which the incorporation of a methyl group at the coumarin skeleton near the ester bond linking both moieties led to a steric shielding effect around this functionality.
On the other hand, a conjugate between the coumarin-caged cyclic RGD peptide and ruthenocene, which was selected as a metallodrug model cargo, has been synthesized and characterized. The fact that green-light triggered photoactivation can be efficiently performed both with the caged peptide (18) and with its ruthenocenoyl bioconjugate (21) opens the door to exploring the use of DEAdcCE-caged peptide sequences as selective drug carriers in the context of photocontrolled targeted anticancer strategies. Work is in progress to extend this approach to other coumarin derivatives with improved red-shifted properties, particularly those removable within the optical window of the tissues, as well as to the conjugation between caged peptides and other anticancer agents, including Pt(IV) pro-drugs.
EXPERIMENTAL SECTION
Materials and Methods.
Unless otherwise stated, common chemicals and solvents including Fmoc-protected amino acids, resins and coupling reagents for solid-phase synthesis were purchased from commercial sources and used without further purification. Milli-Q water was directly obtained from a Milli-Q system equipped with a 5000-Da ultrafiltration cartridge. Aluminium plates coated with a 0.2 mm thick layer of silica gel 60 F 254 were used for thin-layer chromatography analyses (TLC), whereas column chromatography purification was carried out using silica gel 60 (230-400 mesh). Analytical reversed-phase HPLC analyses were carried out on a Jupiter Proteo column (250x4.6 mm, 4 m, flow rate: 1 mL/min), using linear gradients of 0.045% TFA in H 2 O (solvent A) and 0.036% TFA in ACN (solvent B). In some cases, small-scale purification was carried out using the same column. Large-scale purification was carried out on a Jupiter Proteo semipreparative column (250 x 10 mm, 10 m, flow rate: 3 mL/min), using linear gradients of After irradiation, the samples were analyzed by reversed-phase HPLC-ESI MS in a Jupiter Proteo C 18 column (250x4.6 mm, 90 Å 4 m, flow rate: 1 mL/min) using linear gradients of 0.1% formic acid in H 2 O (A) and 0.1% formic acid in ACN (B).
Synthesis of the caged amino acid derivatives.
7-(N,N-diethylamino)-4-(1-hydroxyeth-1-yl)-coumarin (1) 7e
A solution of 4-carbaldehyde-7-(N,N-diethylamino)coumarin (2.58 g, 11 mmol) in dry THF (60 mL) was cooled at -78ºC using a mixture of acetone and dry ice and kept under argon atmosphere. Then, a solution of methylmagnesium chloride (6.3 mL, 3 M) in THF was added dropwise and the reaction mixture was stirred for 2 h at -78ºC in the dark. After that, a second portion of methylmagnesium chloride (3.0 mL) was added. After stirring 2 additional hours at -78ºC in the dark, a saturated aqueous solution of ammonium chloride (50 mL) was added and the reaction mixture was allowed to reach room temperature. The mixture was extracted with ethyl acetate (3 x 50 mL). The combined organic layers were dried over Na 2 SO 4 , filtered and the solvent was removed under reduced pressure. The red residue was purified by column chromatography (silica gel, 0-3.5% MeOH in DCM). The appropriate fractions were collected and the solvents were removed to give a 1.94 g (71% yield) of a yellow solid. TLC: R f (5% : 262.14).
7-(N,N-Diethylamino)-4-hydroxymethylcoumarin (2) 7e
4-carbaldehyde-7-(N,N-diethylamino)coumarin (3.71 g, 15.1 mmol) and sodium borohydride (0.57 g, 15.1 mmol) were stirred at room temperature for 4 h in ethanol (300 mL) protected from light. After addition of 1 M HCl (80 mL) and dilution with water (50 mL), the red solution was extracted with DCM (3 x 50 mL). The combined organic layers were washed with water (50 mL), dried over anhydrous MgSO 4 and filtered. 9, 169.5, 169.3, 162.0, 161.9, 156.6, 155.9, 155.1, 154.8, 150.6, 143.9, 143.8, 143.7, 141.2, 127.7, 127.1, 125.2, 124.8, 124.6, 120.0, 119.9, 108.7, 105.5, 105.1, 104.9, 98.0, 83.0, 82.9, 68.4, 68.2, 67.3, 50.9, 50.8, 47.1, 44.7, 36.9, 27.9, 27.8, 20.9, 12.4 3, 169.4, 161.7, 156.3, 155.9, 150.7, 148.8, 143.8, 141.3, 127.7, 127.1, 125.2, 124.4, 120.0, 108.7, 106.8, 105.9, 97.9, 83.1, 67.3, 61.9, 50.9, 47.1, 44.8, 36.8, 27.9, 12.4 197.3, 197.2, 170.1, 170.0, 169.5, 169.3, 159.4, 155.9, 150.9, 147.3, 147.0, 143.9, 143.8, 141.3, 127.7, 127.1, 125.2, 124.8, 124.7, 120.0, 119.3, 119.1, 110.4, 107.8, 97.7, 83.0, 82.9, 68.1, 67.9, 67.3, 67.2, 53.4, 50.8, 50.8, 47.1, 44.9, 37.0, 36.9, 27.9, 27.8, 20.9, 20.8, 12.4 
Fmoc-Asp(DEATCM)-O t Bu (6)
Lawesson's reagent (1.18 g, 2.92 mmol) was added to Fmoc-Asp(DEACM)-OtBu (4, 1 g, 1.56 mmol) in toluene (50 mL). The mixture was stirred overnight at 70ºC under an argon atmosphere and protected from light. After that, the solvent was evaporated under vacuum and the resulting crude was purified via column chromatography (silica gel, 0-1% MeOH in DCM) 197.0, 170.3, 169.3, 159.1, 155.9, 151.0, 143.8, 141.3, 141.1, 127.7, 127.1, 125.2, 124.5, 121.0, 120.0, 110.3, 108.2, 97.5, 83.1, 67.3, 61.6, 53.4, 50.9, 47.1, 44.9, 36.8, 27.9, 12.4 2H, m), 7.57-7.53 (2H, m), 7.45-7.27 (5H, m), 6.70 (1H, m), 6.64 (1H, m), 6.57-6.52 (1H, m), 6.07 (1H, m), 5.73 (1H, br t), 4.56 (1H, m), 4.35 (2H, m), 4.18 (1H, m), 3.46-3.36 (4H, m), 3.02 (2H, m) 9, 170.0, 169.4, 169.2, 155.9, 155.8, 155.3, 151.8, 151.6, 151.5, 151.3, 143.8, 143.7, 141.2, 127.4, 127.0, 125.1, 119.9, 114.6, 113.8, 110.7, 110.6, 106.5, 104.8, 104.4, 97.5, 82.9, 68.3, 67.2, 55.4, 55.3, 50.9, 47.1, 44.9, 36.9, 29.7, 27.9, 27.8, 21.0, 12.4 6, 170.2, 169.3, 155.9, 155.0, 151.7, 145.2, 143.7, 141.3, 127.7, 127.1, 125.1, 125.0, 120.0, 114.4, 113.7, 110.6, 107.0, 106.5, 97.4, 83.1, 67.2, 61.7, 55.9, 51.0, 47.1, 44.9, 36.9, 27.9, 12.4 
Fmoc-Asp(DEAdcCE)-OH (9)
A solution of HCl in 1,4-dioxane (20 mL, 100 mmol) was added to a Fmoc-Asp(DEAdcCE)-OtBu (7, 600 mg, 0.85 mmol). The reaction mixture was stirred in the dark at 50ºC during 15 h and then concentrated under reduced pressure. The compound was used directly in the assembly of the caged peptide. 1 H NMR (400 MHz, CDCl 3 ) δ (ppm): 7.75 (2H, d, J= 7.2 Hz), m), 7.38 (3H, t, J=7.6 Hz), m), m), m), m), 5.82 (1H, m), m), m), 4.19 (1H, m), m), 3.11 (2H, m) , 1.59 (3H, m), 1.22 (6H, m). 13 C NMR (100 MHz, CDCl 3 ) δ (ppm): 172.1, 169.6, 169.1, 155.8, 155.7, 155.2, 151.7, 151.5, 143.5, 143.4, 141.1, 127.6, 126.9, 124.9, 119.8, 115.6, 113.5, 110.7, 106.3, 104.1, 103.9, 97.4, 72.0, 71.0, 67.2, 61.5, 54.8, 49.9, 46.8, 44.8, 42.7, 36.7, 29.5, 21.0, 12.6 4, 172.17, 170.1, 156.1, 155.0, 151.7, 146.0, 143.8, 141.4, 127.9, 127.3, 125.2, 125.0, 120.1, 115.8, 113.6, 111.2, 107.1, 105.7, 97.7, 72.4, 71.3, 67.5, 61.8, 55.3, 50.3, 47.2, 45.3, 43.0, 36.9, 12.6 
Synthesis DEAdcCE-caged RGD peptide (18)
Solid-phase peptide syntheses were performed manually in a polypropylene syringe fitted with a polyethylene disc. Standard Fmoc/tBu chemistry was used with 2-chlorotrityl chloride resin (f = [M+2H] 2+ : 520.7698).
Synthesis of ruthenocenoyl-peptide conjugates (20 and 21)
Ruthenocene-c(RGD(DEAdcCE)fK) conjugate (20). To a solution of ruthenocene carboxylic acid (0.35 mg, 1.3 mol equiv.) and HATU (0.51 mg, 1.05 mol equiv.) in anhydrous DMF (0.2 mL), DIPEA (2 µL, 10 mol equiv.) was added. After stirring for 5 min at room temperature, the reaction mixture was added to peptide 18 (1.0 mg, 0.91 µmol) previously dissolved in anhydrous DMF (0.2 mL) and DIPEA (1 µL, 5 mol equiv.). After stirring for 2 h at room temperature and protected from light, the solvent was evaporated in vacuo and the conjugate was purified by semipreparative HPLC (gradient from 50 to 100% B in 30 min, flow rate: 3 mL/min, R t = 9.5 min). Overall yield (synthesis + purification): 0.57 mg of a orange solid, 46%. 1007.3565).
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